Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CFTR | P13569 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699348 | 0.85 | CFTR (0.38) | PLAUTDP1CFTRHSD17B10HTT | |
| SCHEMBL14783292 | 0.85 | TDP1 (0.46) | PLAUTDP1HSD17B10HTTKDM4E | |
| SCHEMBL2372260 | 0.85 | CFTR (0.38) | PLAUTDP1CFTRHSD17B10HTT | |
| SCHEMBL2168565 | 0.84 | ALDH1A1 (0.36) | TDP1CFTRHSD17B10HTTKDM4E | |
| SCHEMBL14784037 | 0.81 | CYP3A4 (0.39) | PLAUTDP1CFTRHSD17B10KDM4E | |
| SCHEMBL14784661 | 0.79 | P2RX7 (0.40) | CFTRKDM4EALDH1A1MAPT | |
| SCHEMBL14782957 | 0.77 | PLAU (0.42) | PLAUTDP1ALDH1A1 | |
| SCHEMBL588905 | 0.77 | TDP1 (0.44) | PLAUTDP1HSD17B10HTTPDPK1 | |
| SCHEMBL14720790 | 0.74 | TDP1 (0.43) | PLAUTDP1HSD17B10HTTKDM4E | |
| SCHEMBL2371687 | 0.74 | KDM4E (0.55) | HTTKDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2755652-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | Novartis AG (CH) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038390-A1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | claimed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
| WO-2011113894-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | PLAU 4269/4885TDP1 3387/4885CFTR 1/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | PLAU 4348/4885TDP1 3839/4885CFTR 1/4885 |
| US-20110230483-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | PLAU 4269/4885TDP1 3387/4885CFTR 1/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | PLAU 4422/4885TDP1 2668/4885CFTR 1/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | PLAU 4332/4885TDP1 3600/4885CFTR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.